Tejaswini Kulkarni is a Respiratory physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 139 publications with 2,118 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 1 Feb 2024.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202521 payments$18,347openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year202519 payments$11,215openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.1%Kinase inhibitor42.9%Ofev100%Part D≥16 patientsPyridone35.2%Pirfenidone100%Part D<11 patientsMetabolism & gastrointestinal
21.9%Corticosteroid11.4%Prednisone100%Part D<11 patientsProton pump inhibitor10.5%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Face Mask Detection System Using Deep Learning: A Comprehensive Survey
Communications in computer and information science
2025 - TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity
Nature Communications
2025 - Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial
American Journal of Respiratory and Critical Care Medicine
2025 - Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
BMC Pulmonary Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”